Molecular Partners AG
MOLN
Company Profile
Business description
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
Contact
Wagistrasse 14
Schlieren
Zurich8952
CHET: +41 447557700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
134
Stocks News & Analysis
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
stocks
SpaceX jumps 19% in debut, but hurdles lie ahead
Pre-IPO holders could start selling later this summer, and earnings will be an important test.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,134.50 | 21.10 | 0.23% |
| CAC 40 | 8,350.87 | 150.08 | 1.83% |
| DAX 40 | 24,635.30 | 425.59 | 1.76% |
| Dow JONES (US) | 51,202.26 | 353.51 | 0.70% |
| FTSE 100 | 10,471.72 | 167.84 | 1.63% |
| HKSE | 24,829.11 | 111.01 | 0.45% |
| NASDAQ | 25,888.84 | 79.18 | 0.31% |
| Nikkei 225 | 69,305.85 | 3,285.81 | 4.98% |
| NZX 50 Index | 13,372.49 | 21.38 | -0.16% |
| S&P 500 | 7,431.46 | 37.16 | 0.50% |
| S&P/ASX 200 | 8,922.80 | 15.80 | 0.18% |
| SSE Composite Index | 4,068.58 | 37.06 | 0.92% |